Scil Technology, a company engaged in drug development, formulation and analytics, is a wholly owned subsidiary of BioNet Holding.
Scil Technology CEO Christian Nafe said the grant will enable them to explore an innovative, causal treatment for a debilitating, chronic disease with a huge unmet medical need.
"We have long-standing experience with the controlled, sustained release of therapeutically active proteins for regenerative purposes, and we will now apply our know-how to optimize the product profile," Nafe said.